Definitive Healthcare (NASDAQ:DH) Coverage Initiated at BTIG Research

Research analysts at BTIG Research initiated coverage on shares of Definitive Healthcare (NASDAQ:DH) in a note issued to investors on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $7.00 price target on the stock. BTIG Research’s price target indicates a potential upside of 53.51% from the stock’s previous close.

A number of other equities research analysts also recently commented on DH. JPMorgan Chase & Co. downgraded Definitive Healthcare from a “neutral” rating to an “underweight” rating and decreased their target price for the stock from $7.00 to $5.00 in a research report on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft decreased their price objective on Definitive Healthcare from $7.00 to $5.00 and set a “hold” rating on the stock in a report on Friday, August 9th. Needham & Company LLC reissued a “hold” rating on shares of Definitive Healthcare in a report on Tuesday, August 6th. Morgan Stanley decreased their price target on shares of Definitive Healthcare from $9.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 6th. Finally, Barclays dropped their price objective on shares of Definitive Healthcare from $6.00 to $4.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $5.81.

Definitive Healthcare Price Performance

Shares of NASDAQ:DH opened at $4.56 on Tuesday. The company has a market capitalization of $537.78 million, a P/E ratio of -2.61, a P/E/G ratio of 6.38 and a beta of 1.33. Definitive Healthcare has a 1-year low of $3.19 and a 1-year high of $10.62. The firm’s 50 day simple moving average is $4.65 and its two-hundred day simple moving average is $5.91. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.40 and a quick ratio of 2.40.

Definitive Healthcare (NASDAQ:DH) last announced its quarterly earnings data on Monday, August 5th. The company reported $0.09 EPS for the quarter, meeting the consensus estimate of $0.09. Definitive Healthcare had a positive return on equity of 0.98% and a negative net margin of 156.65%. The business had revenue of $63.70 million for the quarter, compared to the consensus estimate of $63.19 million. During the same period in the previous year, the business earned $0.08 earnings per share. The business’s revenue was up 4.4% on a year-over-year basis. Research analysts expect that Definitive Healthcare will post 0.07 EPS for the current fiscal year.

Institutional Trading of Definitive Healthcare

Several institutional investors and hedge funds have recently made changes to their positions in DH. Norden Group LLC bought a new position in Definitive Healthcare in the first quarter worth approximately $83,000. Sanctuary Advisors LLC purchased a new stake in shares of Definitive Healthcare during the 2nd quarter worth $85,000. Canada Pension Plan Investment Board bought a new stake in Definitive Healthcare during the second quarter valued at about $109,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Definitive Healthcare by 31.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,292 shares of the company’s stock valued at $116,000 after purchasing an additional 5,083 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new position in Definitive Healthcare in the first quarter worth about $120,000. 98.67% of the stock is currently owned by institutional investors.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.